Dennis; and Nevalainen, Marja T., "Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation." (2014) 
INTRODUCTION
Development of metastatic disease is one of the key challenges in clinical management of prostate cancer (PC) (1) . While localized PC can be effectively managed by surgery and radiation, the single greatest cause of PC morbidity and mortality is due to formation of distant metastases (2) (3) (4) (5) (6) .
Identification of the molecular changes leading to metastatic dissemination of PC is critical for development of therapeutic interventions to prevent PC progression to the lethal metastatic form of the disease.
Interleukin-6 (IL-6) is a multifunctional cytokine implicated in PC pathogenesis (7) . IL-6 and IL-6 receptors are expressed in PC, with elevated expression in high Gleason score PCs (8, 9) .
Concomitantly, IL-6 has been found to be elevated in the sera of patients with castrate-resistant prostate cancer (CRPC), and IL-6 serum levels correlate with markers of PC progression (10) (11) (12) (13) (14) (15) (16) . Furthermore, IL-6 is expressed at high levels in the androgen-independent PC cell lines PC3 and DU145 (15) , while the androgen-dependent PC cell line LNCaP expresses lower IL-6 levels (17). IL-6 binds to the IL-6 receptor, a complex which is composed of two subunits: IL-6-R alpha (IL-6-specific) and gp130 (shared by IL-6 and related cytokines) (5, 18, 19) . IL-6 first binds to the IL-6R alpha subunit (20) , which then leads to recruitment of the signal-transducing gp130 subunit. Association of gp130 with IL-6 and IL-6R alpha leads to formation of the high-affinity IL-6 receptor complex and homodimerization of two gp130 subunits, resulting in activation of downstream Jak1/2-Stat3, ERK1/2-MAPK and/or PI3K-Akt signaling in PC cells (5, 19, (21) (22) (23) (24) . In androgen receptor (AR)-positive PC cell lines, it has been suggested that some of the biological effects of IL-6 are mediated via IL-6 induction of AR signaling (25) (26) (27) .
The existing literature on IL-6 regulation of PC cell growth and viability have been controversial, including reports documenting both growth-stimulatory and inhibitory effects (28) (29) (30) (31) (32) (33) (34) . Our previous work demonstrated that Stat3 activation predominantly affects PC progression by inducing metastatic behavior of PC cells in vitro and massive metastasis formation in vivo, rather than promoting PC cell 5 growth (35, 36) . Given that Stat3 is one of the key IL-6-activated signaling molecules in PC, we hypothesized that IL-6 promotes metastatic progression of PC.
Here, we show that the IL-6 protein is expressed in the majority of distant metastases of clinical PCs. IL-6 induced a robust increase in PC metastasis formation in nude mice in an experimental metastasis assay, which was accompanied by IL-6-driven PC cell migration and heterotypic adhesion in vitro. We further demonstrate that IL-6 stimulation leads to activation of Jak1/2 and predominantly Stat3 signaling pathway in AR-negative and AR-positive PC cells. Most important from a therapeutic perspective, pharmacological targeting of Jak1/2 by a potent adenosine triphosphate (ATP)-competitive small-molecule inhibitor of Jak1/2 kinase, AZD1480 (37) prevented IL-6-driven development of a migratory PC cell phenotype in vitro and suppressed IL-6-driven metastatic dissemination of PC in nude mice. In summary, Jak1/2 may represent a therapeutic target proteins for PC, and prevention of metastatic progression of primary PC in patients could potentially be achieved by small-molecule Jak1/2 inhibitors currently in clinical development (38, 39) .
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MATERIALS AND METHODS
Clinical samples of distant metastases of PCs. Archival and de-identified, formalin-fixed, paraffin-embedded specimens of distant metastases of clinical PCs (n=87) (regional lymph nodes, n=36; bone, n=3; other organs, n=48) (Table 1) Immunostaining of paraffin-embedded tissue sections. Immunohistochemistry of distant PC metastases was performed as described previously (35, 36, (40) (41) (42) . The primary antibody IL-6 mAb (Santa Cruz Biotechnology; sc-130326) was used at a concentration of 5µg/ml. Boyden chamber migration assay. DU145 and CWR22Rv1 cells were cultured in 1% CS-FBS, phenol-red free RPMI medium in the presence or absence of IL-6 (5 nM) for 72 h. In the indicated treatment groups, the cells had been infected with lentiviruses expressing control-shRNA, Stat3-shRNA and/or ERK1/2-shRNA 24 h prior to the start of the IL-6 treatment. Also, in the indicated treatment groups, AZD1480 (800 nM) had been added to the culture medium 1 h prior to the start of the IL-6 treatment. The cells were counted and suspended to the upper chambers (2.5 x 10 4 cells/chamber) of the motility chamber system (8.0 µm pore size; BD BioSciences, #353097) using FBS (10%) as the chemoattractant, as described previously (35, 43) . After 16 h, the cells that had traversed the membrane pores were fixed, stained and counted. Each experiment was repeated four times.
Enzyme-linked immunosorbent assay (ELISA
Protein solubilization, immunoprecipitation and immunoblotting. CWR22Rv1, DU145 and LNCaP cells were solubilized and immunoprecipitations and immunoblottings were performed as described previously (35, 36, (43) (44) (45) (46) were purchased from Taconic (Germantown, NY) and SCID mice (for CWR22Rv1 cells) were purchased from the Jackson Laboratory (Bar Harbor, ME), and cared for according to institutional guidelines. DU145 and CWR22Rv1 cells were infected with IL-6 lentivirus (MOI=5) alone or in combination with Stat3-shRNA lentivirus (MOI=5) and/or ERK1/2-shRNA (MOI=5) lentivirus. After 24 h, 1 x 10 6 cells were suspended in 0.2 ml of PBS and injected into the lateral tail veins of nude mice using a 27-gauge needle, as described previously (35, 36, 43) . In some of the experiments, the mice were treated daily by oral gavage of AZD1480 at 50 mg/kg body weight or vehicle (0.5% HPMC/0.1%
Tween-80) starting on day 3 until the mice were sacrificed (8 weeks after cell inoculation). The lungs were perfused with 1.5 ml of 15% India Ink dye in 3.7% formalin, removed and bleached in Fekete's solution (70% ethanol, 3.7% formaldehyde, 0.75M glacial acetic acid). The livers were fixed in 10%
formalin. Lung surfaces were photographed and number of surface lung metastases was scored.
Statistics. Statistical analyses are provided in Suppl. Methods.
RESULTS
IL-6 is expressed in the majority of distant metastases of clinical PCs.
To test the hypothesis that IL-6 promotes metastatic behavior of human PC cells, we first determined the frequency of IL-6 expression in clinical PC metastases (n=87) using immunohistochemical detection of IL-6 in paraffinembedded tissue sections. Representative prostate cancer metastases positive or negative for IL-6 are presented in Figure 1A . A positive immunoreaction for IL-6 was detected in 78% (68/87) of epithelial cells in PC metastases (Table 1 ). In PC metastases to regional lymph nodes, an intense immunoreaction for PC was detected in 89% (32/36) of the specimens, while IL-6 was expressed in 2 out of 3 bone metastases. Additionally, IL-6 was expressed in 71% (34/48) of PC metastases to distant organs other than bone. In summary, our results indicate that the majority of PC metastases robustly express IL-6
protein. DU145 cells were stained for the presence of α-tubulin using FITC-conjugated secondary antibodies (Fig. 2B ). IL-6 (5 nM) induced outward polarization of microtubules from the centrosomes, forming a dense meshwork facing the plasma membrane. In contrast, the microtubule network in control DU145 cells remained disrupted, which is characteristic of non-migratory cells (Fig. 2B) .
IL-6 induces
To investigate if IL-6 disrupts homotypic adhesion of PC cells, we examined the effects of IL-6 on DU145 and CWR22Rv1 cells cultured on Matrigel, a collagen-rich extracellular matrix that provides a more physiological growth environment than plastic. DU145 cells (Fig. 2C ) and CWR22Rv1 cells (Suppl. and to HBMEC cells by 125% (p=0.0079) (Fig. 2D ). In addition, IL-6 increased binding of CWR22Ev1 and Jak1 in DU145 cells, while Jak1 was not expressed in LNCap and CWR22Rv1 cells (Fig. 3A (iii) ).
In CWR22Rv1 cells, IL-6 activated only Stat3 but not ERK1/2 or Akt (Suppl. Figs. 3A and 3B ). Next, we generated lentiviruses expressing shRNAs targeting Stat3, ERK1 and ERK2, and verified protein knockdown efficiency in DU145 cells by Western blotting (Fig. 3B) . To evaluate the contributions of (Fig. 3D ). In conclusion, the data presented here demonstrate that Stat3 signaling pathway predominantly mediates IL-6-induced PC cell migration and heterotypic adhesion in DU145 and CWR22Rv1 cells, while ERK1/2 may also contribute to mediation of IL-6 effects in DU145 cells to a lesser extent.
Pharmacological targeting of Jak2 by AZD1480 suppresses IL-6-induced Stat3 and ERK1/2
signaling and development of a migratory PC cell phenotype. Since Jak1 and Jak2 are the key tyrosine kinases activated by IL-6 in PC cells, we wanted to determine if the small-molecule Jak1/2-inhibitor AZD1480 (37) is capable of suppressing IL-6-induced metastatic behavior of human PC cells
in vitro. We first tested the efficacy of AZD1480 in blocking IL-6-activated cell signaling in PC cells.
AZD1480 inhibited IL-6-induced phosphorylation of Stat3 by approximately 50% (IC50) at a concentration of 9.4 nM in DU145 cells, while the IC50s for IL-6-induced ERK1 and ERK2 phosphorylation were 26 and 21 nM, respectively (Fig. 4A) . Next, we evaluated if AZD1480 suppresses IL-6-driven migration of DU145 cells (Fig. 4B ). DU145 cells were treated with or without recombinant IL-6 (5 nM) for 72 h in the presence or absence of AZD1480 (800 nM), after which equal numbers of cells per group were assayed for migratory ability in Boyden chambers for 16 h. IL-6 increased migration of DU145 cells by 48% (p=0.057), which was potently suppressed by AZD1480 (p=0.029) (Fig. 4B) . Western blotting of cell lysates from parallel wells indicated that AZD1480 primarily inhibited Stat3 and ERK1 phosphorylation, with less inhibition of ERK2 phosphorylation, during longterm IL-6 treatment of DU145 cells (Fig 4B) . Similarly, AZD1480 inhibited (p<0.0001) effectively IL-6-induced (p=0.002) migration of CWR22Rv1 cells (Suppl. Fig. 3C ).
To investigate if AZD1480 reduces heterotypic adhesion of PC cells to endothelial cells, DU145
PC cells were treated with recombinant IL-6 (5 nM) or vehicle with or without AZD1480 (800 nM) for 72 h and assayed for binding to HUVEC and HBMEC cells (Fig. 4C) . Increased heterotypic adhesion of DU145 cells to HUVEC (43%) (p<0.0001) and HBMEC cells (63%) (p<0.0001) induced by IL-6 was effectively blocked by AZD1480 (HUVEC, p=0.0022); HBMEC, p=0.0011) (Fig. 4C) . Similarly, increased heterotypic adhesion of CWR22Rv1 cells to HBMEC cells by IL-6 (p=0.04) was inhibited by AZD1480 (p<0.0001).
14 Finally, we evaluated if the ability of AZD1480 to block IL-6-driven metastatic behavior of PC cells was due to induction of apoptosis in PC cells. Cell viability of DU145 cells cultured with or without IL-6 and/or AZD1480 was determined by MTT assay (Fig. 4D ). IL-6 showed no effect on viability or growth of DU145 cells, indicating that IL-6-driven metastasis formation was not due to IL-6-stimulated PC cell proliferation. At the same time, AZD1480 failed to decrease the number of viable DU145 cells, indicating that suppression of PC cell migration and heterotypic adhesion by AZD1480
was not caused by AZD1480-induced PC cell death (Fig. 4D) . In summary, the data presented here demonstrate that AZD1480 specifically blocked the stimulatory effects of IL-6 on PC cell migration and heterotypic adhesion, rather than affecting PC cell viability. (Fig. 5) . To evaluate if AZD1480 was able to suppress IL-6-driven metastatic progression of PC, mice were treated daily by oral gavage of AZD1480, starting on day 3 until sacrifice. AZD1480 significantly 15 suppressed IL-6-driven metastases formation in these mice (232, S.E.M = 31) (p<0.0001), compared to the IL-6 expressing group without AZD1480 treatment (787, S.E.M. = 92) (Fig. 5) . Collectively, these data demonstrate that pharmacological inhibition of Jak1/2 effectively prevents IL-6-driven metastatic colonization of human PC cells in nude mice. (35, 36) . While IL-6 can promote AR signaling in some PC cell models (25) (26) (27) , a recent study demonstrated that IL-6 secreted by endothelial cells promoted metastatic behavior of PC cells via downregulation of AR (53) . Loss of AR signaling, in turn, resulted in increased TGF-beta production, followed by induction of epithelial-to-mesenchymal transition (EMT) and acquisition of an invasive PC cell phenotype (53) . Our data presented here, however, show that IL-6 directly promoted metastatic processes through Jak1/2 signaling independently of AR, since DU145 cells are negative for expression of functional AR. In other words, IL-6 is capable of promoting metastatic behavior of PC cells independently of the AR-TGF-beta-axis. Future work will need to determine if IL-6 is capable of promoting metastatic processes simultaneously through multiple signaling pathways, including Jak1/2-Stat3, Jak1/2-ERK1/2 and AR-TGF-beta in PC cells positive for AR expression.
Stat3 and ERK1/2 mediate IL-6-driven metastases formation in nude mice
DISCUSSION
The finding of key clinical importance in the present work is that pharmacological targeting of IL-6-Jak1/2-Stat3-signaling by the Jak1/2 inhibitor AZD1480 effectively suppressed IL-6-induced migratory PC cell phenotype and metastatic dissemination in nude mice. This is critically important since numerous Jak1/2 inhibitors are currently in active clinical development for hematopoietic proliferative disorders and malignancies (38, 39) . Jak1/2 inhibitors could potentially provide an adjuvant therapy for organ-confined or locally-advanced PC as a strategy to prevent metastases development after primary treatment. In addition, Jak1/2 inhibitors might provide therapeutic benefit for treatment of existing metastases in both hormone-responsive and CR PC. In the present work, we also demonstrated that IL-6 is expressed in the majority of distant metastases of clinical PCs, similar to what we have previously shown for active Stat3 expression in clinical PC metastases (35) . Future work should establish if autocrine IL-6 production in PC predicts early development of recurrent metastatic PC.
Moreover, it will be important to evaluate if IL-6 expression in PC metastases predicts early PC-specific death. Finally, IL-6 production/positivity of clinical PCs may serve as a biomarker to identify patients who would be most responsive to Jak2-inhibitor-based therapies. Siltuximab (CNTO328), a monoclonal antibody against IL-6, has been evaluated in several Phase I and II trials in CRPC in combination with chemotherapy or in post-chemotherapy setting (54-56). The efficacy of siltuximab was limited in these studies (54) (55) (56) . However, this may be due to the fact that no patient selection based on Il-6 positivity or Stat3 activation of CRPC was conducted.
In summary, the findings presented in this work are the first to demonstrate induction of metastatic processes in PC by IL-6-Jak1/2-Stat3/ERK1/2 pathways, and the therapeutic potential of pharmacological Jak1/2 inhibition as a novel treatment strategy for advanced, metastatic PC. 
